| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10964014 | Vaccine | 2015 | 7 Pages |
Abstract
Immune responses to PCV13 are robust in adults â¥18 years of age, with highest responses observed in the youngest subgroup. Based on its safety and immunologic profile, PCV13 may serve an important therapeutic role in younger adults, particularly those with underlying medical conditions who have an increased risk of serious pneumococcal infections.
Keywords
GMFROPAGMTIPDPPSV23PCV13SAEStreptococcus pneumoniaeAdultsgeometric mean fold risePneumococcal diseaseInvasive pneumococcal diseaseadverse eventSerious adverse eventOpsonophagocytic activityGeometric mean titer23-Valent pneumococcal polysaccharide vaccine13-Valent pneumococcal conjugate vaccineCommunity-acquired pneumoniaCaP
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
K.A. Bryant, R. Frenck, A. Gurtman, J. Rubino, J. Treanor, A. Thompson, T.R. Jones, V. Sundaraiyer, L.M. Baxter, W.C. Gruber, E.A. Emini, D.A. Scott, B. Schmoele-Thoma,